Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

CMC and Bioprocess Blog

Execution-focused articles on CMC strategy, bioprocess scale-up, tech transfer, CDMO selection, and GMP readiness for process development scientists and manufacturing leaders scaling biologics into regulatory-ready therapies.

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Innovation

Cell and gene therapies rely on the fragile integrity of life itself—a single cell surviving through an unforgiving journey from lab to patient

Bioprocessing

Biologics development is full of hidden pitfalls, from selecting the right cell line to navigating analytical assessments that can make or break a therapy’s success.

Bioprocessing

How can small biotech companies navigate increasing molecular complexity, tight budgets, and the ever-present pressure to accelerate timelines while ensuring long-term process success?

Bioprocessing

Is your process model gathering dust while real-world decisions march on without it?

Bioprocessing

Bioprocess development lies at the heart of modern biotechnology, turning innovative molecules into life-changing therapies.

Bioprocessing

Biologics development is full of hidden pitfalls, from selecting the right cell line to navigating analytical assessments that can make or break a therapy’s success.

Bioprocessing

How can small biotech companies navigate increasing molecular complexity, tight budgets, and the ever-present pressure to accelerate timelines while ensuring long-term process success?

Bioprocessing

Is your process model gathering dust while real-world decisions march on without it?

Bioprocessing

Bioprocess development lies at the heart of modern biotechnology, turning innovative molecules into life-changing therapies.

Bioprocessing

Bioreactor scale-up failures are still one of the top reasons promising cell therapies never reach the clinic. Traditional “power per volume” scale-up is often just a best guess—putting product quality and timelines at risk.

Bioprocessing

Can computational fluid dynamics (CFD) join the ranks of everyday tools in bioprocess engineering—right alongside spreadsheets and pH meters?

Data & Analytics

How do you actually measure and shrink your true environmental impact, when most data is missing and every facility operates on a different baseline?

Data & Analytics

Is your manufacturing strategy bleeding money in ways you can’t see?

Data & Analytics

Biotechnology is often perceived as a field exclusively for those with a background in biology.

Data & Analytics

Bioprocess development has long been recognized for its complexity, requiring rigorous experimentation, considerable time, and substantial resources. Yet a shift is underway.

Data & Analytics

ELISA (Enzyme-linked Immunosorbent Assay) has been a workhorse in biotech laboratories for decades.

Biotech Success

Ever watched judges’ faces light up during your pitch?

Biotech Success

Ever stood in front of a room full of executives, your heart pounding, wondering why your brilliant science isn’t connecting?

Biotech Success

What happens when therapeutic innovation meets real patient urgency?

Biotech Success

Real urgency in healthcare means balancing safety, impact, and accessibility—not just speeding to market.

Biotech Success

What’s the single most formidable hurdle for a promising biotech breakthrough? It’s crafting a robust CMC (Chemistry, Manufacturing, and Controls) strategy.

Biotech Success

Bioprocess development and manufacturing are often perceived as sources of potential high-stakes problems, frequently cited as contributing to program failures.

Innovation

Manufacturing under GMP with no established playbook isn’t for the faint-hearted—especially when your therapeutic platform is first-in-class and the regulatory template hasn’t been written yet.

Innovation

What if the best way to unlock durable, broad-spectrum immunity is to rethink the very vessels delivering our vaccines?

Innovation

Translating science into real-world impact isn’t just about groundbreaking ideas—it’s a marathon of mindset, collaboration, and clarity.

Innovation

What if healing large tissue gaps was less about replacing what’s lost, and more about empowering the body to mend itself?

Innovation

What does it actually take to turn a cell therapy idea into a viable therapeutic—especially when the hurdles are higher than ever and every experiment carries real consequences for your runway?

Innovation

When it comes to neurodegenerative disease, few diagnoses evoke as much dread as Parkinson’s.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.


No spam. Unsubscribe anytime.